Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

“The NIH decision to restrict access to key genomic and medical datasets hinders global cooperation at a time when coordinated action is needed”, said Anjee Davis (Fight Colorectal Cancer, Springfield ...

Every 2 years, researchers from the American Cancer Society (ACS) publish a comprehensive report using data from multiple ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

If generative AI could contribute in the slightest to such discoveries—as has been promised since the start of the AI ...

Robert F. Kennedy Jr. said the percentage of Americans with chronic diseases has gone up 20 times in six decades. That makes ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

In Greece, cancer claims 95 lives daily and costs €1.9 billion annually, making it the second leading cause of death after ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Researchers from University of California San Diego have linked a bacterial toxin called colibactin to the increase in early-onset cases of colorectal cancer.

The findings highlight mixed trends in death and incidence rates across cancer types and based on race, ethnicity, and sex ...

Children living in impoverished neighborhoods have a higher risk of developing cancer and experiencing early death, according ...